NB
NBIX
HealthcareNeurocrine Biosciences
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
9
EarningsBullishPR NewswireMay 5, 2026
Neurocrine Q1 Revenue $811M +44% YoY; Agrees to Acquire Soleno Therapeutics
- ▸Q1 net product sales $811.0M, up 44% year-over-year
- ▸Definitive agreement to acquire Soleno Therapeutics announced
- ▸Acquisition includes VYKAT XR for Prader-Willi syndrome treatment
- ▸Acquisition expected to close in Q2 2026
- ▸Strong top-line growth driven by core product portfolio